当前位置： SCI文献检索 > BONE MARROW TRANSPLANTATION期刊下所有文献 > Integration of humoral and cellular HLA-specific immune responses in cord blood allograft rejection.

Integration of humoral and cellular HLA-specific immune responses in cord blood allograft rejection.

Abstract：

:In allo-stem cell transplantation (SCT), it is unclear whether donor-specific anti-HLA Abs (DSAs) can actually mediate graft rejection or if they are simply surrogate markers for the cellular immunity that causes graft rejection. Here, we first analyzed a case of cord blood allograft rejection in which DSA and cytotoxic T lymphocyte (CTL) specific for donor HLA-B*54:01 were detected at the time of graft rejection. Both the DSA and CTL inhibited colony formation by unrelated bone marrow mononuclear cells sharing HLA-B*54:01, suggesting that the humoral and cellular immune responses were involved in the graft rejection. Interestingly, the DSA and CTL were also detected in cryopreserved pre-transplant patient blood, raising a hypothesis that the presence of anti-HLA Abs could be an indicator for corresponding HLA-specific T cells. We then evaluated the existence of HLA-specific CD8(+) T cells in other patient blood specimens having anti-HLA class I Abs. Interferon-γ enzyme-linked immunospot assays clearly confirmed the existence of corresponding HLA-specific T-cell precursors in three of seven patients with anti-HLA Abs. In conclusion, our data demonstrate that integrated humoral and cellular immunity recognizing the same alloantigen of the donor can mediate graft rejection in DSA-positive patients undergoing HLA-mismatched allo-SCT. Further studies generalizing our observation are warranted.

journal_name

Bone Marrow Transplant

journal_title

Bone marrow transplantation

authors

Hanajiri R,Murata M,Sugimoto K,Murase M,Sakemura R,Goto T,Watanabe K,Imahashi N,Terakura S,Ohashi H,Akatsuka Y,Kurahashi S,Miyamura K,Kiyoi H,Nishida T,Naoe T

doi

10.1038/bmt.2015.119

subject

Has Abstract

pub_date

2015-09-01 00:00:00

pages

1187-94

issue

9

eissn

0268-3369

issn

1476-5365

pii

bmt2015119

journal_volume

50

pub_type

杂志文章

相关文献

BONE MARROW TRANSPLANTATION文献大全
  • Risk factors for acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: retrospective analysis of 73 patients who received cyclosporin A.

    abstract：:Cyclosporin A (CsA) has been used most widely as an immunosuppressive agent for preventing graft-versus-host disease (GVHD). To explore the risk factors including CsA blood levels for grades II-IV acute GVHD, we retrospectively analyzed the data of patients who underwent allogeneic hematopoietic stem cell transplantat...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1705834

    authors： Izumi N,Furukawa T,Sato N,Okazuka K,Tsukada N,Abe T,Yano T,Kurasaki T,Masuko M,Toba K,Takahashi M,Aizawa Y

    更新日期：2007-11-01 00:00:00

  • Short-term ex vivo activation of splenocytes with anti-CD3 plus IL-2 and infusion post-BMT into mice results in in vivo expansion of effector cells with potent anti-lymphoma activity.

    abstract：:We investigated the proliferation and therapeutic utility of anti-CD3 activated splenocytes infused into mice following BMT. Using congenic mouse strains we demonstrated that splenocytes activated briefly ex vivo with anti-CD3 plus IL-2 (T-activated killer cells or T-AK) and infused intravenously following BMT had a g...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Katsanis E,Xu Z,Anderson PM,Dancisak BB,Bausero MA,Weisdorf DJ,Blazar BR,Ochoa AC

    更新日期：1994-10-01 00:00:00

  • Process of allogeneic hematopoietic cell transplantation decision making for older adults.

    abstract：:Allogeneic hematopoietic cell transplantation (alloHCT) may be the only curative option for some older adults with hematologic malignancies, and its associated risks of significant morbidity and mortality warrant a clear, informed decision-making process. As older adults have not been transplanted routinely until rece...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：10.1038/bmt.2015.241

    authors： Randall J,Keven K,Atli T,Ustun C

    更新日期：2016-05-01 00:00:00

  • Endocrine late effects in children who underwent bone marrow transplantation: review.

    abstract：:With the increasing use and success of BMT, larger numbers of children survive transplantation. Still, cancer treatment in children causes damage to the endocrine glands, often inducing growth deficiency, pubertal delay and thyroid dysfunction. This paper will deal with some of the most common endocrine disorders rela...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：

    authors： Cohen A,Rovelli R,Zecca S,Van-Lint MT,Parodi L,Grasso L,Uderzo C

    更新日期：1998-04-01 00:00:00

  • High dose therapy and autologous bone marrow transplant (ABMT) in acute leukemia: is purging necessary?

    abstract：:Multiple clinical studies have been undertaken to evaluate the role of ABMT in relapse, in second and subsequent remission (CR greater than or equal to 2), and in first remission (CR1). The value of these high dose cytoreductive programs with ABMT is not yet known. No randomized studies have been done yet indicating t...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：

    authors： Dicke KA,Spinolo JA

    更新日期：1989-01-01 00:00:00

  • Chest health surveillance utility in the early detection of bronchiolitis obliterans syndrome in children after allo-SCT.

    abstract：:To prospectively assess whether periodic chest health surveillance is beneficial for the early detection of bronchiolitis obliterans syndrome (BOS) in children after allo-SCT. Children up to 18 years of age receiving allo-SCT from September 2009 to September 2011 were included. Surveillance consisted of the following:...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/bmt.2012.228

    authors： Gassas A,Craig-Barnes H,Dell S,Doyle J,Schechter T,Sung L,Egeler M,Palaniyar N

    更新日期：2013-06-01 00:00:00

  • Autologous bone marrow transplantation for patients with acute myeloblastic leukemia in relapse after autologous blood stem cell transplantation.

    abstract：:Leukemic relapse remains the most frequent reason for treatment failure in patients with acute myeloblastic leukemia (AML) treated with autologous blood stem cell transplantation (ABSCT). The aim of this study was to evaluate the possible role of autologous bone marrow transplant (ABMT) in patients with AML who relaps...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：

    authors： de la Rubia J,Sanz GF,Martín G,Sempere A,Picón I,Carral A,Larrea L,Martínez J,Soler MA,Bonanad S,López F,Jarque I,Sanz MA

    更新日期：1996-12-01 00:00:00

  • Low incidence of molecular evidence for tumour in PBPC harvests from patients with high risk Ewing tumours.

    abstract：:Reverse transcriptase polymerase chain reaction (RT-PCR) was applied to evaluate the frequency of tumour cells in PBPC products from 15 high risk Ewing tumour (ET) patients who were treated according to EICESS 92 with high-dose chemotherapy (HDC) and stem cell rescue. Initial tumour cell contamination of the bone marr...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1701924

    authors： Fischmeister G,Zoubek A,Jugovic D,Witt V,Ladenstein R,Fritsch G,Höcker P,Gadner H,Kovar H

    更新日期：1999-08-01 00:00:00

  • Risk factors and mortality predictors of hepatic veno-occlusive disease after pediatric hematopoietic stem cell transplantation.

    abstract：:A cohort of 138 children with 144 hematopoietic stem cell transplantation (HSCT) performed in 1997-2006 were analyzed to evaluate risk factors and mortality predictors of hepatic veno-occlusive disease (VOD). Nineteen patients (13.2%) developed VOD (nine boys, median age 3.5 years) at 1-21 days after HSCT (median 13 d...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1705835

    authors： Cheuk DK,Wang P,Lee TL,Chiang AK,Ha SY,Lau YL,Chan GC

    更新日期：2007-11-01 00:00:00

  • Severe migratory polyarthritis following in vivo CAMPATH-1G.

    abstract：:CAMPATH-1G is an IgG2b rat antihuman (CDw52) monoclonal antibody (MoAb) which is currently being used for T cell depletion in the setting of allogeneic bone marrow transplantation (BMT). In addition it elicits substantial lymphoid depletion, an effect which is being explored for remission induction in patients with ly...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Varadi G,Or R,Rund D,Orbach H,Slavin S,Nagler A

    更新日期：1995-12-01 00:00:00

  • Peripheral blood stem cell (PBSC) collection in extremely low-weight infants.

    abstract：:While PBSC collection has become a safe procedure for adults, only a few reports exist about its efficacy, safety and feasibility in paediatric patients, especially extremely low-weight infants. We describe successful PBSC collection in three infants of less than 10 kg body weight (BW; range: 6.92-9.4 kg) suffering fr...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Nussbaumer W,Schönitzer D,Trieb T,Fink FM,Maurer-Dengg K,Höcker P,Wagner A,Schwaighofer H,Nachbaur D,Niederwieser D

    更新日期：1996-07-01 00:00:00

  • Intestinal obstruction caused by bezoar: a rare complication after bone marrow transplantation.

    abstract：:Gastrointestinal complications are described frequently after preparation of patients for bone marrow transplantation (BMT). Two patients who underwent BMT developed complications due to gastrointestinal bezoars. One patient developed intestinal obstruction, which necessitated emergency surgery, and the other patient ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Ben-Yehuda A,Ben-Yehuda-Salz D,Or R,Landau EH,Krausz MM

    更新日期：1989-01-01 00:00:00

  • Blood tacrolimus concentrations in bone marrow transplant patients undergoing plasmapheresis.

    abstract：:Microangiopathic hemolytic anemia (MAHA) is a well-described complication of stem cell transplantation. Plasmapheresis is one modality utilized as therapy for patients who develop this complication. However, plasmapheresis may alter whole blood levels of certain medications and its effect on tacrolimus in bone marrow ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1702174

    authors： Hale GA,Reece DE,Munn RK,Kniska AB,Phillips GL

    更新日期：2000-02-01 00:00:00

  • Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings.

    abstract：:Among 42 consecutive recipients of unrelated marrow were 39 HLA-A, -B, -DR identical, matched unrelated donors (MUD) and three with one HLA antigen mismatch. The majority were genomically typed for DRB, DQA, DQB and DPB. The recipients of MUD marrow were compared with 39 recipients of marrow from HLA-identical sibling...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Ringdén O,Remberger M,Persson U,Ljungman P,Aldener A,Andström E,Aschan J,Bolme P,Dahllöf G,Dalianis T

    更新日期：1995-04-01 00:00:00

  • A randomized trial of amifostine as a cytoprotectant for patients receiving myeloablative therapy for allogeneic hematopoietic stem cell transplantation.

    abstract：:We initiated a randomized study of amifostine (the organic thiophosphate formerly known as WR-2721) given to patients during myeloablative conditioning therapy for allogeneic bone marrow transplantation. Amifostine was given at a dose of 1000 mg/day of conditioning and was well tolerated if attention was given to seru...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1038/sj.bmt.1704521

    authors： Hwang WY,Koh LP,Ng HJ,Tan PH,Chuah CT,Fook SC,Chow H,Tan KW,Wong C,Tan CH,Goh YT

    更新日期：2004-07-01 00:00:00

  • Myeloablative and reduced-intensity conditioning in HLA-haploidentical peripheral blood stem cell transplantation using post-transplant cyclophosphamide.

    abstract：:We conducted two parallel prospective, multicenter, phase II studies to evaluate the safety and efficacy of HLA-haploidentical peripheral blood stem cell transplantation using post-transplant cyclophosphamide (PTCy-haploPBSCT) following myeloablative conditioning (MAC, n = 50) and reduced-intensity conditioning (RIC, ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,多中心研究

    doi：10.1038/s41409-018-0279-1

    authors： Sugita J,Kagaya Y,Miyamoto T,Shibasaki Y,Nagafuji K,Ota S,Furukawa T,Nara M,Akashi K,Taniguchi S,Harada M,Matsuo K,Teshima T,Japan Study Group for Cell Therapy and Transplantation (JSCT).

    更新日期：2019-03-01 00:00:00

  • Enteral budesonide in treatment for mild and moderate gastrointestinal chronic GVHD.

    abstract：:Budesonide (BUD) is a steroid with a low bioavailability, which has been used for the treatment of oral manifestations of chronic GVHD (cGVHD). We retrospectively evaluated the efficacy of BUD in the treatment of gastrointestinal cGVHD. Thirteen patients (median age 47 years) receiving BUD for the treatment of cGVHD a...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2008.209

    authors： Andree H,Hilgendorf I,Leithaeuser M,Junghanss C,Holzhueter S,Loddenkemper C,Steiner B,Freund M,Wolff D

    更新日期：2008-10-01 00:00:00

  • Successful vidarabine therapy for adenovirus type 11-associated acute hemorrhagic cystitis after allogeneic bone marrow transplantation.

    abstract：:A 36-year-old man underwent an allogeneic BMT for acute lymphoblastic leukemia. Eighteen days later the patient developed sudden onset of painful, gross hematuria due to adenovirus type 11 infection that did not respond to conservative therapy. There was an increase in serum creatinine levels and delayed recovery of t...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Kitabayashi A,Hirokawa M,Kuroki J,Nishinari T,Niitsu H,Miura AB

    更新日期：1994-11-01 00:00:00

  • Alternative donor SCT for the treatment of MHC class II deficiency.

    abstract：:MHC Class II deficiency is a rare primary immunodeficiency disease characterized by absent HLA Class II expression resulting in CD4 lymphopenia, lack of Ag-specific responses and recurrent infection. Without successful allogeneic SCT, most children succumb to infection within the first decade of life. To date, alterna...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2012.140

    authors： Small TN,Qasim W,Friedrich W,Chiesa R,Bleesing JJ,Scurlock A,Veys P,Sparber-Sauer M

    更新日期：2013-02-01 00:00:00

  • Second marrow transplants for recurrence of haematological malignancy.

    abstract：:Nine patients with haematological malignancy relapsed 3-32 months after receiving cyclophosphamide 120 mg/kg, 12-14 Gy fractionated total body irradiation and an HLA-identical sibling bone marrow transplant. They were reconditioned with melphalan 180-220 mg/m2 and retransplanted using the same donor and the same cyclo...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Atkinson K,Biggs J,Concannon A,Dodds A,Dale B,Norman J

    更新日期：1986-12-01 00:00:00

  • Elimination of malignant clonogenic T cells from human bone marrow using chemoimmunoseparation with 2'-deoxycoformycin, deoxyadenosine and an immunotoxin.

    abstract：:Autologous bone marrow transplantation may contribute to the treatment of several types of lymphoreticular malignancies. Recent studies have suggested that a combination of chemoseparation and immunoseparation may be more effective than either modality alone in eliminating malignant cells from human bone marrow. In th...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Montgomery RB,Kurtzberg J,Rhinehardt-Clark A,Haleen A,Ramakrishnan S,Olsen GA,Peters WP,Smith CA,Haynes BF,Houston LL

    更新日期：1990-06-01 00:00:00

  • Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation.

    abstract：:Donor lymphocyte infusions (DLI) are used to treat relapsed haematological diseases after allogeneic stem cell transplantation (SCT). We treated seven patients with DLI for indolent non-Hodgkin's lymphoma relapsed after SCT. In available blood and bone marrow samples, lymphoma cells were analysed by real-time quantita...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1704290

    authors： Mandigers CM,Verdonck LF,Meijerink JP,Dekker AW,Schattenberg AV,Raemaekers JM

    更新日期：2003-12-01 00:00:00

  • Alternative donor transplant of benign primary hematologic disorders.

    abstract：:Hematopoietic SCT is currently the only curative therapy for a range of benign inherited and acquired primary hematologic disorders in children, including BM failure syndromes and hemoglobinopathies. The preferred HLA-matched sibling donor is available for only about 25% of such children. However, there has been subst...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：10.1038/bmt.2015.1

    authors： Tolar J,Sodani P,Symons H

    更新日期：2015-05-01 00:00:00

  • Peripheral blood stem cell for haploidentical transplantation with post-transplant high dose cyclophosphamide: detailed analysis of 181 consecutive patients.

    abstract：:While bone marrow (BM) grafts were initially used for T-replete HLA-haploidentical related donors transplantation (Haplo-SCT) with post-transplantation cyclophosphamide (PT-Cy), the use of peripheral blood stem cell (PBSC) remains debated. We thus conducted a detailed analysis evaluating the incidence, risk factors, a...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,多中心研究

    doi：10.1038/s41409-019-0500-x

    authors： Granata A,Fürst S,Bramanti S,Legrand F,Sarina B,Harbi S,De Philippis C,Faucher C,Chabannon C,Lemarie C,Calmels B,Mariotti J,Maisano V,Weiller PJ,Mokart D,Vey N,Bouabdallah R,Castagna L,Blaise D,Devillier R

    更新日期：2019-11-01 00:00:00

  • Results of single and double autografts for high-risk neuroblastoma patients.

    abstract：:Although intensive therapy with autologous bone marrow transplantation (ABMT) has improved the outcome of advanced neuroblastoma, nearly half the patients with this disease still relapse after a single ABMT. In our previous study, 10 of 22 patients relapsed within 16 months post-transplantation. Predictive risk-factor...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Kawa-Ha K,Yumura-Yagi K,Inoue M,Park DY,Okamura T,Yasui M,Oota H,Sakata N,Yoneda M,Imura K

    更新日期：1996-06-01 00:00:00

  • Management of acute graft-versus-host disease.

    abstract：:Current graft-versus-host disease (GVHD) prophylaxis is not uniformly successful. Since the development of GVHD has a profound impact on transplant success, treatment is required. The mainstay of therapy has been glucocorticoids (steroids), along with anti-thymocyte globulin, cyclosporine, monoclonal antibodies, and a...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：

    authors： Deeg HJ,Henslee-Downey PJ

    更新日期：1990-07-01 00:00:00

  • Prolonged remission of longstanding systemic lupus erythematosus after autologous bone marrow transplant for non-Hodgkin's lymphoma.

    abstract：:We describe a patient with longstanding steroid-dependent systemic lupus erythematosus (SLE) in whom clinical and serological remission was achieved following high-dose therapy and autologous bone marrow rescue for high-grade non-Hodgkin's lymphoma. However, 3 years later, autoimmune disease re-presented in the form o...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1700815

    authors： Snowden JA,Patton WN,O'Donnell JL,Hannah EE,Hart DN

    更新日期：1997-06-01 00:00:00

  • Are new conditioning regimens for transplants in acute myelogenous leukemia better?

    abstract：:Pretransplant conditioning regimens designed to decrease leukemia relapse and increase leukemia-free survival in allotransplants in acute myelogenous leukemia (AML) were developed recently. We review studies of new regimens containing drugs like busulfan, cytarabine, melphalan or etoposide as well as novel radiation s...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：

    authors： Aurer I,Gale RP

    更新日期：1991-04-01 00:00:00

  • Reevaluation of the National Institutes of Health criteria for classification and scoring of chronic GVHD.

    abstract：:We used the National Institutes of Health (NIH) criteria for the diagnosis, classification and scoring of chronic GVHD (cGVHD) to reevaluate patients with cGVHD originally diagnosed using classic criteria. We retrieved data from 236 patients diagnosed with cGVHD on the basis of classic criteria. Excluding 20 'liver-al...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2009.320

    authors： Kim DY,Lee JH,Lee JH,Kim SH,Lim SN,Kim SD,Choi Y,Lee YS,Kang YA,Kang SI,Seol M,Ryu SG,Lee KH

    更新日期：2010-07-01 00:00:00

  • Evaluation of infectious complications after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide following reduced-intensity and myeloablative conditioning: a study on behalf of the Francophone Society of Stem Cell

    abstract：:Several approaches have been developed to overcome historical barriers associated with poor outcomes in the setting of HLA-haploidentical allogeneic transplantation (HaploSCT). Here, we examine the outcome of patients with various hematological disorders undergoing HaploSCT with high-dose, post-transplantation cycloph...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,多中心研究

    doi：10.1038/s41409-019-0475-7

    authors： Fayard A,Daguenet E,Blaise D,Chevallier P,Labussière H,Berceanu A,Yakoub-Agha I,Socié G,Charbonnier A,Suarez F,Huynh A,Mercier M,Bulabois CE,Lioure B,Chantepie S,Beguin Y,Bourhis JH,Malfuson JV,Clément L,Peffault de

    更新日期：2019-10-01 00:00:00